Literature DB >> 26880473

Haematological cancer: Ibrutinib supercharges CAR T cells.

Peter Sidaway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26880473     DOI： 10.1038/nrclinonc.2016.28

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Authors:  Joseph A Fraietta; Kyle A Beckwith; Prachi R Patel; Marco Ruella; Zhaohui Zheng; David M Barrett; Simon F Lacey; Jan Joseph Melenhorst; Shannon E McGettigan; Danielle R Cook; Changfeng Zhang; Jun Xu; Priscilla Do; Jessica Hulitt; Sagar B Kudchodkar; Alexandria P Cogdill; Saar Gill; David L Porter; Jennifer A Woyach; Meixiao Long; Amy J Johnson; Kami Maddocks; Natarajan Muthusamy; Bruce L Levine; Carl H June; John C Byrd; Marcela V Maus
Journal:  Blood       Date:  2016-01-26       Impact factor: 22.113
  1 in total
  2 in total

Review 1.  Cellular therapy: Immune-related complications.

Authors:  Joseph H Oved; David M Barrett; David T Teachey
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

Review 2.  Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies.

Authors:  Yizhao Han; Zhuojun Liu; Jia Liu; Weiqi Yan; Yuanshi Xia; Shuhua Yue; Jian Yu
Journal:  Biomed Res Int       Date:  2020-09-17       Impact factor: 3.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.